Braveheart Bio, Inc.

BRVE

Healthcare Biotechnology

EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

19.62 0.88 −4.29%
Market cap
$1.8B
P/E
n/m
Fwd P/E
—
Dividend yield
—
F-score
n/a
ROIC
−28.7%
Net debt / EBITDA
1.3×
Payout ratio
—

Ratios over time Q4 FY25 to Q3 FY26

Returns on capital

ROIC was -28.7% in Q3 FY26, the lowest of these four quarters. ROE, at 0.0%, is far above it because equity is small against the capital the business uses.

ROEROIC
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
ROE0.0%0.0%0.0%0.0%
ROIC0.0%0.0%0.0%−28.7%

Debt

Net debt is 11.58× a year’s EBITDA.

Net debt / EBITDA
Q4 FY25Q1 FY26Q2 FY26Q3 FY26
Net debt / EBITDA12.8×5.3×7.7×11.6×
Older periods Dec '25 Mar '26 Jun '26 Sep '26
Current Ratio

+3 more quarters

17.03 8.11 13.63 21.57
Net Debt/EBITDA
12.77 5.34 7.72 11.58
Debt/Equity
0.00 0.00 0.00 0.00
Free Cash Flow per Share
(0.33) (0.76) (2.29) (0.47)
Book value per Share
(17.15) (11.42) (12.96) 9.55
Free Cash Flow
(1.27) (5.22) (16.94) (24.37)
Other line items

Show all line items

Columns are period end dates · fundamentals updated 12 Nov 2026